LGND: Ligand Pharmaceuticals Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,294.26
Enterprise Value ($M) 1,271.30
Book Value ($M) 700.91
Book Value / Share 39.59
Price / Book 1.85
NCAV ($M) 105.28
NCAV / Share 5.95
Price / NCAV 12.29

Profitability (mra)
Return on Invested Capital (ROIC) 0.07
Return on Assets (ROA) 0.07
Return on Equity (ROE) 0.09

Liquidity (mrq)
Quick Ratio 12.72
Current Ratio 14.15

Balance Sheet (mrq) ($M)
Current Assets 237.43
Assets 833.06
Liabilities 132.15
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 131.31
Operating Income 9.82
Net Income 52.15
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 49.58
Cash from Investing -11.68
Cash from Financing -59.95

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G Macquarie Group Ltd 5.66 57.97
02-13 13G/A Janus Henderson Group Plc 7.70 7.00
02-13 13G/A Vanguard Group Inc 10.76 1.81
02-12 13G Goldman Sachs Group Inc 6.80
01-22 13G/A BlackRock Inc. 17.00 6.19

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange
2023-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-03-28 19,181 73,881 25.96
2024-03-27 49,203 191,807 25.65
2024-03-26 12,505 107,915 11.59
2024-03-25 15,674 107,055 14.64

(click for more detail)

Similar Companies
KROS – Keros Therapeutics, Inc. KYMR – Kymera Therapeutics, Inc.
LBPH – Longboard Pharmaceuticals, Inc. LNTH – Lantheus Holdings, Inc.
LRMR – Larimar Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io